Charles G. Drake mainly focuses on Immunology, Immunotherapy, Immune system, Cancer and Internal medicine. The study incorporates disciplines such as Cancer research and Prostate cancer in addition to Immunology. His work deals with themes such as Cytotoxic T cell and Radiation therapy, which intersect with Immunotherapy.
In his study, which falls under the umbrella issue of Cancer, Metastasis is strongly linked to Adverse effect. His Internal medicine study integrates concerns from other disciplines, such as Surgery and Oncology. In his study, Avelumab and Tolerability is strongly linked to Colorectal cancer, which falls under the umbrella field of Oncology.
Charles G. Drake spends much of his time researching Internal medicine, Prostate cancer, Oncology, Immunology and Cancer research. Enzalutamide, Ipilimumab, Nivolumab, Phases of clinical research and Clinical trial are among the areas of Internal medicine where Charles G. Drake concentrates his study. The subject of his Prostate cancer research is within the realm of Cancer.
His Melanoma research extends to Cancer, which is thematically connected. Charles G. Drake usually deals with Oncology and limits it to topics linked to Docetaxel and Placebo. His Cancer research study combines topics in areas such as Cytotoxic T cell, Blockade, CD8 and Immunotherapy.
His scientific interests lie mostly in Cancer research, Prostate cancer, Immunotherapy, Internal medicine and Oncology. His Cancer research research includes elements of Cytotoxic T cell and T cell, CD8, Immune system. The concepts of his Prostate cancer study are interwoven with issues in Prostate and Docetaxel.
Immunotherapy is a subfield of Cancer that Charles G. Drake studies. His biological study spans a wide range of topics, including Inflammation, Transcriptome, Melanoma and Intensive care medicine. His studies in Oncology integrate themes in fields like Pembrolizumab, Placebo, Clinical endpoint and Antitumor activity.
His main research concerns Internal medicine, Oncology, Immunotherapy, Prostate cancer and Cancer research. In his study, Therapeutic approach and Kidney cancer is inextricably linked to Atezolizumab, which falls within the broad field of Oncology. His Immunotherapy study is related to the wider topic of Cancer.
His Cancer research includes themes of Inflammation and Intensive care medicine. His research integrates issues of Progression-free survival, Overall survival and Consensus conference in his study of Prostate cancer. His research in Cancer research intersects with topics in Cytotoxic T cell, Immune system, Major histocompatibility complex and Vaccination.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger.
The New England Journal of Medicine (2012)
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer;Scott S. Tykodi;Scott S. Tykodi;Laura Q.M. Chow;Wen Jen Hwu.
The New England Journal of Medicine (2012)
Immune checkpoint blockade: a common denominator approach to cancer therapy
Suzanne L. Topalian;Charles G. Drake;Drew M. Pardoll.
Cancer Cell (2015)
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer;Charles G. Drake;Ira Wollner;John D. Powderly.
Journal of Clinical Oncology (2010)
A draft map of the human proteome
Min Sik Kim;Sneha M. Pinto;Derese Getnet;Raja Sekhar Nirujogi.
Inflammation in prostate carcinogenesis
Angelo M. De Marzo;Angelo M. De Marzo;Elizabeth A. Platz;Siobhan Sutcliffe;Jianfeng Xu.
Nature Reviews Cancer (2007)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon;Charles G. Drake;Howard I. Scher;Karim Fizazi.
Lancet Oncology (2014)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.
Suzanne L Topalian;Charles G Drake;Drew M Pardoll.
Current Opinion in Immunology (2012)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng Ryong Woo;Meghan E Turnis;Monica V Goldberg;Jaishree Bankoti.
Cancer Research (2012)
Role of LAG-3 in regulatory T cells.
Ching Tai Huang;Creg J. Workman;Dallas Flies;Xiaoyu Pan.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: